These analyses aim to comparatively evaluate the persistence on treatment of different biological disease-modifying antirheumatic drugs (bDMARDs) when administered in monotherapy compared with combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis (RA) patients receiving first-line biologics.

Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases

Silvagni, Ettore
Primo
Conceptualization
;
Bortoluzzi, Alessandra
Secondo
Conceptualization
;
Govoni, Marcello
Penultimo
Supervision
;
Scirè, Carlo Alberto
Ultimo
Methodology
2018

Abstract

These analyses aim to comparatively evaluate the persistence on treatment of different biological disease-modifying antirheumatic drugs (bDMARDs) when administered in monotherapy compared with combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis (RA) patients receiving first-line biologics.
Silvagni, Ettore; Bortoluzzi, Alessandra; Carrara, Greta; Zanetti, Anna; Govoni, Marcello; Scirè, Carlo Alberto
File in questo prodotto:
File Dimensione Formato  
bmjopen-2017-021447.pdf

accesso aperto

Descrizione: Full text editoriale
Tipologia: Full text (versione editoriale)
Licenza: Creative commons
Dimensione 843.2 kB
Formato Adobe PDF
843.2 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2395148
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 23
social impact